Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD
Clinical journal of the American Society of Nephrology : CJASN | 21 Apr 2016
R Provenzano, A Besarab, CH Sun, SA Diamond, JH Durham, JL Cangiano, JR Aiello, JE Novak, T Lee, R Leong, BK Roberts, KG Saikali, S Hemmerich, LA Szczech, KP Yu and TB Neff
Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with nondialysis CKD.
* Data courtesy of Altmetric.com